Opdivo could revolutionize cancer treatment with subcutaneous administration
- FDA accepts Bristol-Myers’ application for subcutaneous Opdivo formulation
- Opdivo is a blockbuster cancer drug with over $9 billion in revenue last year
- Application covers Opdivo co-formulated with Halozyme’s Enhanze drug-delivery technology
- Opdivo could become the first subcutaneously administered PD-1 inhibitor
- Target action date for the application is Feb. 28, 2025
Bristol Myers Squibb announced that the FDA has accepted its application for the approval of a subcutaneous formulation of its popular cancer drug, Opdivo. The application includes Opdivo co-formulated with Halozyme’s Enhanze drug-delivery technology, covering all previously approved adult, solid-tumor Opdivo indications. Opdivo, which generated over $9 billion in revenue last year, currently requires intravenous administration. If approved, Opdivo will become the first subcutaneously administered PD-1 inhibitor. The FDA has set a target action date for the application on Feb. 28, 2025.
Factuality Level: 9
Factuality Justification: The article provides factual information about Bristol Myers Squibb’s application for approval of a subcutaneous formulation of Opdivo, including details about the drug, the application, and the collaboration with Halozyme. The information is clear, relevant, and free from bias or sensationalism.
Noise Level: 3
Noise Justification: The article provides relevant information about Bristol Myers Squibb’s application for approval of a subcutaneous formulation of Opdivo, a blockbuster cancer drug. It includes details about the drug, the technology involved, and the potential impact of FDA approval. The article stays on topic and supports its claims with specific examples and data. However, it lacks in-depth analysis, accountability, and actionable insights, which prevents it from receiving a higher rating.
Financial Relevance: Yes
Financial Markets Impacted: Bristol Myers Squibb
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The news article pertains to a financial company, Bristol Myers Squibb, and its application for approval of a subcutaneous formulation of its cancer drug. There is no mention of an extreme event or its impact.
Public Companies: Bristol Myers Squibb (BMY)
Private Companies: Halozyme
Key People: Colin Kellaher (Author)
Reported publicly:
www.marketwatch.com 
